Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02533505 · ClinicalTrials.gov registry record · Phase 4
Phase IV O2 Consumption Study in COPD Patients.
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT02533505 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 51 participants.
The verdict
NCT02533505, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
A Phase IV study evaluating changes in oxygen consumption and cardiac function in Subjects with Chronic obstructive pulmonary disease (COPD) with resting hyperinflation after administration of Symbicort pMDI 160/4.5 μg.
Interventions
- DRUG Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol
- DRUG Matching Placebo pMDI 160/4.5 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-08-25 |
| Est. Completion | 2016-08-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02533505
The ClinicalTrials.gov registry entry for NCT02533505 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol is the first listed.
NCT02533505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02533505 about?
NCT02533505 is a clinical study titled "Phase IV O2 Consumption Study in COPD Patients.". A Phase IV study evaluating changes in oxygen consumption and cardiac function in Subjects with Chronic obstructive pulmonary disease (COPD) with resting hyperinflation after administration of Symbicort pMDI 160/4.5 μg.
What is the current status of trial NCT02533505?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2015-08-25. Estimated completion is 2016-08-12.
What interventions are being tested in trial NCT02533505?
The interventions under investigation include: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol (DRUG), Matching Placebo pMDI 160/4.5 μg (DRUG).
Who is sponsoring clinical trial NCT02533505?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.